van der Lei S, Puijk RS, Dijkstra M, Schulz HH, Vos DJW, De Vries JJJ.
Lancet Oncol 2025; 26: 187-199.
Some 296 patients with up to 10 metastases less than 3cm in diameter were included. After median follow-up of 28.9 months, overall survival was similar in both groups (hazard ratio 1.05, 95 per cent confidence interval 0.69 to 1.58) but ablation therapy had a superior safety profile.
Comment: Are we getting closer to the suggestion that ablation therapy is a reasonable option even for operable liver metastases?
.png)
.jpg){kind=logo}
